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Activated Kras Alters Epidermal Homeostasis
of Mouse Skin, Resulting in Redundant Skin
and Defective Hair Cycling
Anandaroop Mukhopadhyay1,2, Suguna R. Krishnaswami1,2 and Benjamin D.-Y. Yu1
Germline mutations in the RAS–mitogen-activated protein kinase (RAS/MAPK) pathway are associated with
genodermatoses, characterized by cutaneous, cardiac, and craniofacial defects, and cancer predisposition.
Whereas activating mutations in HRAS are associated with the vast majority of patients with Costello syndrome,
mutations in its paralog, KRAS, are rare. To better understand the disparity among RAS paralogs in human
syndromes, we generated mice that activate a gain-of-function Kras allele (Lox-Stop-Lox (LSL)-KrasG12D)
in ectodermal tissue using two different Cre transgenic lines. Using Msx2-Cre or ligand-inducible keratin 15
(K15)-CrePR, the embryonic effects of activated Kras were bypassed and the effects of KrasG12D expression from
its endogenous promoter were determined. We found that KrasG12D induced redundant skin, papillomas,
shortened nails, and hair loss. Redundant skin was associated with basal keratinocyte hyperplasia and an
increase in body surface area. Paradoxically, KrasG12D also prevented hair cycle activation. We find that KrasG12D
blocks proliferation in the bulge region of the hair follicle, when activated through Msx2-Cre but not through
K15-CrePR. These studies reveal that KRAS, although infrequently involved in RAS/MAPK syndromes, is capable
of inducing multiple cutaneous features that grossly resemble human RAS/MAPK syndromes.
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INTRODUCTION
RAS–mitogen-activated protein kinase (RAS/MAPK) proteins
link extracellular growth factor signals to an internal cascade
of downstream pathways. Activation of RAS can be modu-
lated at many levels, including amount and availability
of ligands, receptors, adaptors, and downstream effectors
(Reuther and Der, 2000; Schubbert et al., 2007). Both
extracellular and intracellular antagonists have been identi-
fied that spatially and temporally attenuate RAS/MAPK
signals (Freeman, 2000). Regulation of RAS/MAPK activation
depends on the steady-state level of guanosine triphosphate
(GTP)-bound RAS. RAS-GTP levels are negatively regulated
by an intrinsic GTPase activity, which is catalyzed by
proteins called GTPase activating proteins or RAS-GAPs
(Yarwood et al., 2006). In cancer, point mutations cause
the loss of one of these two negative feedback mechanisms
and prolong the activation of downstream proteins
(Downward, 2006).
Recently, activating mutations in RAS- and MAPK-encod-
ing genes have been identified in several human syndromes,
including HRAS in Costello (Aoki et al., 2005; Schulz et al.,
2008), KRAS (Schubbert et al., 2006), BRAF, MEK1, and
MEK2 in cardiofaciocutaneous (CFC) (Niihori et al., 2006;
Rodriguez-Viciana et al., 2006), and KRAS, PTPN11, RAF1,
and SOS1 in Noonan syndrome (Schubbert et al., 2006;
Roberts et al., 2007; Tartaglia et al., 2007). These syndromes
and additional syndromes, neurofibromatosis, LEOPARD,
and Legius syndromes, are often referred collectively as
RAS/MAPK syndromes, because they share a defect in a
common signaling pathway (Rodriguez-Viciana et al., 2006;
Brems et al., 2007; Rauen et al., 2008). Three RAS/MAPK
syndromes, Costello, CFC, and Noonan syndromes, share
many phenotypic similarities, including short stature, cranio-
facial dysmorphology, cardiomyopathy, and heart valve
defects. RAS/MAPK syndromes demonstrate more variability
in the degree of neurocognitive impairment, skin manifesta-
tions, cancer risk, and type of cancer predisposition (Roberts
et al., 2006).
A wide range of ectodermal defects have been noted in
RAS/MAPK syndromes, particularly in Costello, CFC, and
Noonan syndrome. Costello syndrome patients classically
have redundant skin, multiple papillomas, and thickened
palms and soles (Hennekam, 2003; Weiss et al., 2004).
Progressive hair loss or thinning is reported in Costello
(36.4%) and CFC (75.9%) patients, but rarely in Noonan
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syndrome. Many of the classic features of these syndromes
were described prior to the discovery of heterogeneous
alleles and genes in RAS/BRAF/MEK, and thus further
delineations may be possible. Nevertheless, the phenotypic
effects in the skin suggest that developmental processes
in skin, brain, and cancer may be uniquely sensitive to
RAS activation and its downstream effectors. Recently, mice
bearing a strong HrasG12V allele have been generated as
possible models of Costello syndrome (Schuhmacher et al.,
2008; Chen et al., 2009). The HrasG12V gain-of-function mice
develop cardiomyopathy and papillomas like Costello
syndrome patients but apparently lack several many other
cutaneous abnormalities.
As noted above, the vast majority of RAS mutations related
to Costello syndrome involve mutations in HRAS. Mutations
in the paralog, KRAS, have also been discovered in associa-
tion with humans with CFC, Costello-like, and Noonan
syndromes, although at much lower frequencies (o5%)
(Zenker et al., 2007). Differences in paralog gene expression,
allele strength, biochemical partners, or early embryonic
requirements could contribute to different outcomes of KRAS
activation during development and different disease out-
comes. To shed light on this question, we investigated the
cutaneous response in mice to a strong KrasG12D allele.
Utilizing a Cre–lox approach to activate Kras in different
compartments of the ectoderm, we find that Kras activation in
the ectoderm has multiple effects on nail, hair, and skin
defects. The single mutant KrasG12D allele induces hyper-
plasia of limited cell types of the skin, including the basal
keratinocytes in the epidermis, sebaceous gland, and outer
root sheath (ORS) of the hair follicle. Paradoxically, KrasG12D
blocks hair cycle activation in the hair follicle but does not
directly affect bulge specification or proliferation.
RESULTS
Previous genetic studies in mice have shown that strong
activating mutations in Kras, such as oncogenic KrasG12D, are
incompatible with fetal development (Shaw et al., 2007).
Similarly, tissue-specific activation of KrasG12D in mice, using
a keratin 14 (K14)-Cre keratinocyte-specific line to activate
KRAS in the ectoderm, also resulted in embryonic lethality
(Tuveson et al., 2004). To bypass lethality and to activate
KRAS in the mouse epidermis and hair follicle, we used
a Msx2-Cre transgenic mouse model, which expresses
Cre recombinase along the midline epidermis, limb ecto-
derm of embryos, and the postnatal hair follicle matrix
(Sun et al., 2000; Pan et al., 2004). Intercrosses between
homozygous Msx2-Cre and hemizygous mice carrying a
conditional knock-in allele of KrasG12D, Lox-Stop-Lox
KrasG12D (LSL-KrasG12D), generated mice in which KrasG12D
activation occurs in the epidermis and hair. Importantly,
expression of KrasG12D remains under the control of its
endogenous promoter and thus recapitulates its normal expres-
sion pattern, dosage, and regulation (Tuveson et al., 2004).
Msx2-Cre; LSL-KrasG12D (hereafter called Msx2-Cre;
KrasG12D) mice were born at near expected Mendelian
frequency (49%, n¼45/92). Msx2-Cre; KrasG12D and control
Msx2-Cre (‘‘wild type’’) neonates were grossly equal in size
and showed no external signs of congenital malformations.
After 1 week of age, Msx2-Cre; KrasG12D mice could be
recognized by the appearance of redundant skin folds on
their face, eyelids, and back (Figure 1a–c). By 2 weeks of age,
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Figure 1. Overview of cutaneous defects in Msx2-Cre; KrasG12D mice. (a) The 10-day-old and (b) 9-week-old Msx2-Cre; KrasG12D (KrasG12D) and control
(wt) littermates demonstrate redundant skin and hair loss phenotypes. (c) Thickened eyelids and (d) shortened nails of Msx2-Cre; KrasG12D and wild-type
littermate mice. Asterisk denotes abnormal short nail and arrowhead identifies coarse volar skin surface of Msx2-Cre; KrasG12Dmice. (e) Papilloma on forepaw of
Msx2-Cre; KrasG12D versus wild-type littermate. (f) Age of onset of progressive cutaneous phenotypes in Msx2-Cre; KrasG12D mice.
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Msx2-Cre; KrasG12D hair became noticeably rough and short
compared with wild-type littermates. This abnormal hair
appearance persisted into adulthood, and hair loss became
apparent after 3 weeks along the midline of the back and
throughout the dorsal head (Figure 1b). In older Msx2-Cre;
KrasG12D mice, the nails also appeared brittle and short
(Figure 1d). These cutaneous changes were observed in 100%
of adult Msx2-Cre; KrasG12D mice (n¼34). None of these
phenotypes were observed in their wild-type littermates or in
LSL-KrasG12D heterozygous mice, which do not have Cre.
Spontaneous papillomas were observed in 78% of Msx2-Cre;
KrasG12D mice as early as 2 weeks of age (Figure 1e and f).
Sites of papilloma formation were highly skewed toward non-
hair-bearing areas such as the perianal, fore/hindpaw, and
head skin. Less than 10% of papillomas developed on back
skin, where hair abnormalities were dominant (Supplemen-
tary Table S1 online). Histologically, the tumors were
consistent with squamous papillomas, and none of the 22
tumors were found to be invasive (Supplementary Figure S1
online). Because of the size of the papillomas (41 cm),
euthanasia of affected animals was performed. These
observations indicate that activation of the KrasG12D allele
in the skin affect the normal homeostasis of the skin and hair
and predispose mice to benign papillomas.
Previous work demonstrated that the Msx2-Cre transgene
is active early in the dorsal ectoderm, as early as E11.5 (prior
to hair development). Thus, when Msx2-Cre mice are
interbred with a Cre-sensitive b-galactosidase reporter in
the ROSA locus (R26R), more extensive recombination can
be detected in the dorsal ectoderm of newborn animals
compared with adjacent lateral areas of the skin (Pan et al.,
2004). The increased severity along the dorsal midline of
Msx2-Cre; KrasG12D animals might be because of increased
Cre activity in the dorsal skin. We sought to determine the
efficiency of recombination at the Kras locus based on the
relative amount of excision of the intervening LSL-stop
cassette, as recombination efficiency can vary between
different genetic loci (Akagi et al., 1997). Quantitative PCR
revealed 1.7 more recombination as measured by the
relative loss of LSL-stop cassette in dorsal than in lateral
whole skin (Supplementary Table S2 online). These findings
indicate that like the ROSA locus, recombination and
activation of KrasG12D is more frequent in the dorsal midline
of Msx2-Cre mice.
Epidermal response to KrasG12D
The epidermis is a stratified epithelium that is continuously
renewed by keratinocyte progenitors located in the basal
layer (Blanpain and Fuchs, 2006). Suprabasal keratinocytes
are postmitotic and differentiate to form a physical and
hydrophobic barrier. To investigate the basis of the Msx2-Cre;
KrasG12D skin phenotype, we analyzed proliferation and
differentiation of the epidermis. The epidermis of Msx2-Cre;
KrasG12D mice was hypercellular and associated with a
dense, hyperproliferative layer of basal keratinocytes
(Figure 2a–c and Supplementary Table S2 online). In cultured
keratinocytes, proliferation of Msx2-Cre; KrasG12D primary
keratinocytes was also accelerated and reached a growth
plateau of approximately twice the density of wild-type
controls before contact inhibition (Figure 2d). Like wild-type
littermates, suprabasal keratinocytes of Msx2-Cre; KrasG12D
mice were postmitotic, and although the epidermis appeared
thicker, Msx2-Cre; KrasG12D mice displayed equal numbers
of nucleated layers (4 to 5 nucleated layers). Each layer
expressed appropriate patterns of differentiation, including
K10 and loricrin. These findings indicate that KrasG12D
primarily affects the basal layer but has little effect on
the kinetics of postmitotic differentiation. As an alternative
to epidermal thickening as a cause for redundant skin,
we considered increased skin surface area as a possible
mechanism. To assess the relative change in body
surface area, the anterior–posterior lengths of skin biopsies
were measured. As skin biopsies varied in size, the contour of
the epidermis was normalized to the length of the biopsy
base. We found that the relative amount of epidermis
produced by Msx2-Cre; KrasG12D mice increased by 9.9%
more than control littermates (Figure 2e). These results
suggest that the redundant skin phenotype in Msx2-Cre;
KrasG12D mice results from basolateral expansion of basal
keratinocytes and the overabundance of body surface area.
Effects of KrasG12D on hair growth
Over the next 2 to 3 weeks of age, the Msx2-Cre; KrasG12D
mice developed progressive hair loss. Significantly, after 3
weeks of age, there was no evidence of new hair growth in
affected areas of the Msx2-Cre; KrasG12D mice, during a
period of the first postnatal hair cycle (Figure 3) (Muller-Rover
et al., 2001). A second assay was used to assess new hair
growth. After trimming the dorsal hair of mice, all 11 (100%)
wild-type littermate mice showed complete hair re-growth in
2 weeks, whereas only 3 of 15 (20%) Msx2-Cre; KrasG12D
mice had signs of new hair re-growth (Figure 3a). Addition-
ally, to determine if activation of a physiologic hair cycle was
merely delayed rather than blocked, we screened for early
anagen gene expression (Shh mRNA) and hair differentiation
(inner root sheath and medulla) over a 30-day window (P18
to P51) in Msx2-Cre; KrasG12D mice (Figure 3b–d). In affected
areas, none of the 16 Msx2-Cre; KrasG12D mice showed signs
of anagen growth or hair differentiation. These findings
indicate that Msx2-Cre; KrasG12D mice have defective
activation of the hair cycle.
Histological and immunofluorescent analysis throughout
these stages consistently revealed an overgrowth of follicular
epithelium resembling ORS cells in Msx2-Cre; KrasG12D mice
(Figure 4a–c). K14, P63, and SOX9 expression confirm the
identity of this tissue (Figure 4d–f and not shown). ORS
hyperplasia also persisted during catagen, when hair follicles
normally involute and regress (Figure 4b and e). Like wild-
type hair follicles, the Msx2-Cre; KrasG12D hair follicles were
nonproliferative and other cells of the hair follicle appeared
to regress normally (not shown). These findings indicate that
the Msx2-Cre; KrasG12D mice enter catagen and that the
KrasG12D ORS is relatively resistant to involution. Using two
markers of apoptosis, TUNEL and phospho-histone H2A
variant X, immunostaining of Msx2-Cre; KrasG12D mice
revealed lack of cell death in the ORS (Figure 4e, not shown).
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These findings indicate that during a normal period of scheduled
cell death, the ORS of Msx2-Cre; KrasG12D mice was resistant to
apoptosis.
The tissue that remained after catagen showed varying
contributions of SOX9-positive cells in the follicular epithe-
lium, ranging from no contribution to approximately half
(Figure 4f). However, the majority of this tissue also expressed
high levels of P-cadherin, which is characteristic of an ORS
subpopulation called the secondary hair germ (Figure 4f)
(Ito et al., 2004; Greco et al., 2009). Failure to initiate a new
hair cycle could reflect absence of or defective activation of
hair follicle stem cells called bulge cells, which are also
derived from ORS tissue (Paus and Cotsarelis, 1999; Tumbar
et al., 2004). By staining for several bulge markers (CD34,
membrane CCAAT-enhancer-binding protein-a (C/EBPa),
and K15), we found that bulge cells were still present
in Msx2-Cre; KrasG12D mice at all stages of development
(Figure 5a–c; not shown) (Bull et al., 2002; Trempus et al.,
2003; Morris et al., 2004). Neither Ki-67-positive nor
proliferating cell nuclear antigen-positive bulge cells could
be detected during any stage of the Msx2-Cre; KrasG12D mice;
e.g., P16 through P77 (Figure 5c). Thus, KrasG12D promotes
the expansion of ORS and secondary hair germ-like cells, but
does not affect the number or identity of the bulge cells.
To determine whether KrasG12D mutations autonomously
block cell division in bulge cells to divide or block their
differentiation, we utilized a ligand-inducible K15-CrePR
model to activate KrasG12D allele in the bulge cells
(Figure 5d). Through the intercross of K15-CrePR; KrasG12D
and homozygous floxed lacZ (R26R) mice, we generated
K15-CrePR; KrasG12D; R26R and littermate controls and
found no significant difference in the percentage of animals
in anagen (Figure 5e). To assess the efficiency of recombina-
tion, the percentage of mice with b-galactosidase-positive
hair follicles was determined. In all, 83.3% of K15-CrePR;
KrasG12D; R26R mice demonstrated b-galactosidase-positive
hair follicles compared with 90% of K15-CrePR; R26R mice
(Figure 5f). Moreover, recombination at the Kras locus was
confirmed by loss of the LSL-cassette in b-galactosidase-
positive hair follicles (Supplementary Table S2 online). Thus,
activation of KrasG12D in bulge cells did not affect their ability
to proliferate and contribute to new hair re-growth.
DISCUSSION
In this study, we investigated the biological response of the
skin and hair to activated Kras to better understand the
developmental consequences of activated RAS. We find that
activated KrasG12D induces global changes to skin and hair
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Figure 2. Ectodermal activation of KrasG12D causes excess epidermis production. (a) Keratin 14 (K14)-positive basal keratinocytes in postnatal day 4 (P4)
Msx2-Cre; KrasG12D and littermate mice. Loricrin (LOR) identifies uppermost differentiated granular layer of the epidermis. (b) Suprabasal differentiation (K10)
and number of stratified layers are similar between Msx2-Cre; KrasG12D and wild-type mice. (c) Ki-67 immunofluorescence in basal epidermis of Msx2-Cre;
KrasG12D mice. (d) Proliferation assay of P2 wild-type (blue) and Msx2-Cre; KrasG12D (red) keratinocytes reveals increased growth and density. (e) Histological
sections demonstrate surface contour of P10 wild-type and Msx2-Cre; KrasG12D mice. Length of the surface contour (red) is normalized to length of biopsy
(black). White scale bar¼ 20mm; black scale bar¼ 200 mm.
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architecture. The resulting phenotype of redundant skin, hair
loss, shortened nails, and perianal papillomas in Msx2-Cre;
KrasG12D mice differed from previous gain-of-function mouse
models utilizing either KrasG12D or HrasG12V alleles. These
studies reveal, to our knowledge, previously unreported roles
for RAS signaling in the regulation of hair and skin
morphogenesis.
Prior to this study, the KrasG12D allele had been studied in
the context of cutaneous and oral mucosal malignancies
through the use of heterotopic promoters, e.g., bi-transgenic
KrasG12D, tetracycline activated (tet-on) promoter (Vitale-
Cross et al., 2004), or tissue-specific activation of KrasG12D
from its endogenous promoter (Tuveson et al., 2004; Caulin
et al., 2007). Heterotopic KrasG12D-tet-on activated expres-
sion induced histological evidence of epidermal hyperplasia
in the skin, oral mucosa, salivary glands, esophagus, stomach
and cervix, and various stages of squamous neoplasias,
ranging from benign papillomas to metastatic carcinomas.
Cre-based studies similarly focused on the neoplastic effects
of endogenous KrasG12D in the postnatal skin, using topically
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Figure 3. Screen for hair cycle activation and maturation in Msx2-Cre; KrasG12D mice. (a) Hair growth in wild-type versus Msx2-Cre; KrasG12D animals at
different stages of development. (b) Immunofluorescence for hair differentiation markers, IRS (irs) and medulla (m), using anti-trichohyalin antibody and keratin
14 (K14), a marker for outer root sheath (ORS), sebaceous gland (sg), and basal epidermal marker. Positive trichohyalin staining in postnatal day 26 (P26) wild
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anagen hair follicle. (d) Hematoxylin stain of telogen hair follicle of wild-type mice compared with abnormal persistence of basaloid keratinocytes. White and
black scale bars¼50 mm.
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delivered ligands to activate Cre recombinase. Whereas
postnatal activation of KrasG12D using a ligand-inducible
K5-CrePR triggered oral epithelial abnormalities and
papillomas (Caulin et al., 2007), prenatal activation of
KrasG12D in the skin ectoderm with K5-Cre caused neonatal
lethality (Tuveson et al., 2004). Thus, many aspects of RAS
function during postnatal development remain unknown.
In addition to cancer, RAS/MAPK mutations are also
associated with developmental disorders. Developmental
consequences in the skin, e.g., redundant skin and hair loss,
however, have not been reported in earlier models of
KrasG12D or HrasG12V gain-of-function mice. Lack of devel-
opmental or major morphological defects in the skin of these
animals could be because of differences in the timing or
pattern of RAS activation or in the case of ectopic promoters,
nonphysiological levels and regulation of KrasG12D gene
expression. In the case of HrasG12V, in which gain-of-function
alleles were introduced into the endogenous locus, differ-
ences in the regulation of RAS paralog gene expression or
biochemical partners could result in differences in overall
phenotype.
The overproduction of skin in Msx2-Cre; KrasG12D mice
indicate that RAS signals may normally participate in
homeostasis of skin production. Skin production as measured
by body surface area is normally kept in balance with
increasing body size. Similar mechanisms maintain organ
size in symmetry with body size (Stern and Emlen, 1999). In
the Msx2-Cre; KrasG12D mouse, the overall increase in body
surface area can be best described phenotypically as excess
skin or redundant skin. Wrinkled, sagging, or loose skin,
which imply changes in skin laxity, were not observed in the
Msx2-Cre; KrasG12D mice. Furthermore, changes in elastin
and collagen were not observed in our studies (Figure 2e; not
shown). Other mouse models with excess skin have been
described, which overexpress transforming growth factor-a or
fibroblast growth factors (FGF7 and FGF10). In these mice,
the skin and basal keratinocytes were also shown to be
hyperproliferative (Guo et al., 1993). Unlike the Msx2-Cre;
wt
So
x9
/P
-c
ad
So
x9
/K
14
γ-
H
2A
X
P10a
b
c
e
f
d P10
P16
100 μm
P21 P20
P16
Kras G12D wt Kras G12D
Figure 4. Outer root sheath (ORS) analysis in Msx2-Cre; KrasG12D mice. (a–c) Histology of postnatal day 10 (P10; anagen), P16 (catagen), P21 (early anagen)
of wild-type and Msx2-Cre; KrasG12D hair follicles. (d) P10 analysis of hyperplastic ORS in Msx2-Cre; KrasG12D mice reveals irregular patterns of keratin 14
(K14)-positive, Sox9-positive ORS growth. (e) Apoptosis of P16 wild-type and Msx2-Cre; KrasG12D hair follicles as detected by phosphorylated histone H2A
variant X (H2AX) staining (green, arrows). (f) Immunofluorescence reveals persistent and abundant secondary hair germ and ORS in telogen of Msx2-Cre;
KrasG12D mice. Solid bracket indicates SOX9-positive cells in the region of the bulge. Dotted line indicates boundary of secondary hair germ in wild-type
and of remnant ORS tissue in Msx2-Cre; KrasG12D mice. Black scale bar (a–c)¼100 mm; white scale bar (d–f)¼ 50mm.
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KrasG12D mice, overexpressed growth factors caused epider-
mal thickening and altered patterns of differentiation. At
a time when redundant skin first became apparent in the
Msx2-Cre; KrasG12D mice, the earliest detectable change was
hyperplasia of the basal layer of the epithelium. These defects
preceded overgrowth of the ORS and sebaceous gland
(Figures 2e and 3b and d). Because epidermal thickening
and increased stratification were absent in the Msx2-Cre;
KrasG12D mice, basolateral expansion of the epidermis
appears to be the primary cause of redundant skin. Additional
studies considering basement membrane production and the
apparent anteroposterior directionality of overgrowth are
needed to further explore the mechanisms of RAS-mediated
body surface area regulation.
Because RAS is regulated by its endogenous promoter in
this experimental model, it seems likely that the affected
tissues reflect cells and developmental processes that are
normally regulated by RAS activation. Endogenous ligands
likely to trigger RAS activation in the epidermis include
members of the epidermal growth factor and FGF family.
Previous studies demonstrate that transforming growth
factor-a, an epidermal growth factor family member, is
constitutively produced by keratinocytes and functions as an
autocrine signal (Guo et al., 1993). FGF ligands such as FGF7
(also called KGF) are instead produced by mesenchyme.
Some aspects of the KrasG12D-induced epidermal phenotype
could be explained by hyperstimulation of both autocrine
and paracrine signaling pathways. As overexpression of these
ligands produced similar phenotypes, it seems likely that one
or more of these growth factors normally have a role in the
allometric regulation of skin production. Overexpression of
the epidermal growth factor receptor, ErbB2a, also induces
hyperplasia of the adnexal structures, including the seba-
ceous gland (Kiguchi et al., 2000), whereas the KrasG12D
allele induces hyperplasia of the sebaceous gland and ORS.
As KrasG12D allele induces a wider spectrum of organ
involvement, it is likely that the epidermal, ORS, and
sebaceous gland hyperplasia represent the normal signaling
domains of all three ligand signals.
A second major phenotype seen in the Msx2-Cre;
KrasG12D mice was progressive hair loss. Although RAS
activation has been implicated in cell cycle arrest in various
experimental models (Lin et al., 1998; Courtois-Cox et al.,
2006), activation of the KrasG12D allele using the bulge Cre
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line, K15-CrePR, was not sufficient to block hair cycling. In
addition, KrasG12D-recombined cells appeared to be capable
of contributing to cells of the hair lineage. The abnormal
morphology of Msx2-Cre; KrasG12D hair follicles might also
prevent the normal activation of bulge and hair germ from
anagen stimulatory signals. During normal hair cycle activa-
tion, anagen stimulatory signals from the dermal papilla are
in close proximity to bulge and hair germ cells (Botchkarev
and Paus, 2003). In the Msx2-Cre; KrasG12D mice, the
persistence of ORS cells during telogen could block this
paracrine signaling event. Conversely, paracrine signals, e.g.,
from abnormal ORS or surrounding tissue, might also affect
hair cycle activation or refractoriness (Plikus et al., 2008). As
additional progenitor populations have now been identified
in the resting hair follicle, additional Cre transgenic
approaches will need to be used to determine if the cell
autonomous effects of KrasG12D differ between different hair
progenitor lineages (Snippert et al., 2010).
Last, although KRAS rarely contributes to the human RAS/
MAPK syndromes, gross similarities in phenotypes between
several cutaneous features of RAS/MAPK syndromes and the
Msx2-Cre; KrasG12D mice were observed. Loose, redundant
skin has been reported in patients with Costello syndrome.
Skin biopsies of Costello patients show degenerate elastic
fibers (Mori et al., 1996), and thus it is believed that
the redundant skin phenotype of Costello syndrome repre-
sents elastin defects. The Msx2-Cre; KrasG12D mice do not
demonstrate loose or sagging skin, which are typical of
mice with elastin/collagen abnormalities, e.g., cutis laxa
(Nakamura et al., 2002; Suzuki et al., 2003). Furthermore, the
Msx2- Cre; KrasG12D mice develop redundant skin in the
dorsal trunk, rather than dorsal hands and feet, which are
commonly affected in Costello syndrome. These differences
could be explained by the Cre driver used in our study.
Nevertheless, it seems possible that epidermal homeostasis
may also contribute to the appearance of redundant skin
in Costello syndrome patients. Another phenotype, hair loss,
is reported in RAS/MAPK syndromes, in particular CFC
(Roberts et al., 2006). Findings from the Msx2-Cre; KrasG12D
mice suggest that one possible mechanism for hair loss in
CFC patients may be hair cycle defects. As mutations in CFC
involve BRAF, MEK1, and MEK2, it seems likely that this
effector pathway has a significant role in regulating
hair cycling. Interestingly, KRAS has been shown to have
strong preference toward RAF activation; whereas HRAS has
preference for phosphoinositol-3-kinase (Yan et al., 1998).
Hair loss in the Msx2-Cre; KrasG12D model and normal hair
homeostasis in HrasG12V gain-of-function mice could
reflect effector preferences of KRAS versus HRAS in the hair
follicle. The studies highlight the degree of plasticity of the
mammalian skin to generate vastly different cutaneous
patterns via modulating a single signaling pathway.
MATERIALS AND METHODS
Mouse breeding and genotyping
Mice were genotyped by PCR analysis of tail biopsy DNA using
primers as previously described (Tuveson et al., 2004). Msx2-Cre
males originated from CD-1 outbred strain, whereas LSL-KrasG12D
strain was derived from C57BL/6 129SvJ. To assess recombination
frequency, skin, dissected hair follicles, and papillomas were lysed
in tail buffer followed by quantitative PCR to assess the loss of
LSL-cassette (LSL-REV 50-GCTGAACTGAGCGAACAAGTGCAA-30;
LSL-FOR 50-TTGCCATCGATCCATCTACCACCA-30). All experiments
were performed with approved animal protocols according to the
institutional guidelines established by the University of California, San
Diego, institutional animal care and use committees.
Histology, in situ hybridization, and immunohistochemistry
Immunohistochemical and immunofluorescent stainings were per-
formed on acetone or paraformaldehyde-fixed tissue in conjunction
with citrate antigen retrieval. The following antibodies were used
for this study: K14 (1:200; Labvision, Fremont, CA), K10 (1:200; Lab-
vision), Loricrin (1:100; gift from Colin Jamora), Ki-67 (1:100;
Labvision), AE13 (1:25; Abcam, Cambridge, MA), AE15 (1:100;
Santa Cruz Biotechnologies, Santa Cruz, CA), CD34-FITC (1:100;
eBioscences, San Diego, CA), p63 4A4 (1:200, Labvision),
C/EBP-a (1:100; Santa Cruz Biotechnologies), C/EBP-b (1:500, Santa
Cruz Biotechnologies), K15 (1:100; Labvision), and phosphorylated
histone H2A variant X (1:100; Cell Signal). In situ hybridizations
were performed as previously described (Brown et al., 2006).
Anti-sense digoxygenin riboprobes were generated according to the
manufacturer’s instructions (Roche Applied Science, Indianapolis,
IN). Shh riboprobes were previously described (Lewis et al., 2001).
K17 riboprobes were transcribed from PCR-generated templates
from exon 1 (sequences available upon request).
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